Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Other Non-Current Assets (2023 - 2025)

Connect Biopharma Holdings' Other Non-Current Assets history spans 3 years, with the latest figure at $45000.0 for Q3 2025.

  • For Q3 2025, Other Non-Current Assets changed N/A year-over-year to $45000.0; the TTM value through Sep 2025 reached $45000.0, changed N/A, while the annual FY2024 figure was $33000.0, 37.5% up from the prior year.
  • Other Non-Current Assets for Q3 2025 was $45000.0 at Connect Biopharma Holdings, roughly flat from $45000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $45000.0 in Q1 2025 and bottomed at $24000.0 in Q4 2023.
  • The 3-year median for Other Non-Current Assets is $45000.0 (2025), against an average of $38400.0.
  • The largest YoY upside for Other Non-Current Assets was 37.5% in 2024 against a maximum downside of 37.5% in 2024.
  • A 3-year view of Other Non-Current Assets shows it stood at $24000.0 in 2023, then soared by 37.5% to $33000.0 in 2024, then surged by 36.36% to $45000.0 in 2025.
  • Per Business Quant, the three most recent readings for CNTB's Other Non-Current Assets are $45000.0 (Q3 2025), $45000.0 (Q2 2025), and $45000.0 (Q1 2025).